On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Rebecca Kristeleit

ResearcherPublications, citations & collaboration network

Rebecca Kristeleit is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Rebecca Kristeleit have?

ScholarIQindexed works

Rebecca Kristeleit has 350 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Rebecca Kristeleit have?

ScholarIQcitation count

Rebecca Kristeleit has 9,058 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Rebecca Kristeleit?

ScholarIQh-index

Rebecca Kristeleit has an h-index of 42 in OpenAlex.

What is the i10-index of Rebecca Kristeleit?

ScholarIQi10-index

Rebecca Kristeleit has an i10-index of 113 in OpenAlex.

What is the ORCID of Rebecca Kristeleit?

ScholarIQorcid

The ORCID for Rebecca Kristeleit is on the source record.

What is the OpenAlex record for Rebecca Kristeleit?

ScholarIQopenalex

The OpenAlex for Rebecca Kristeleit is on the source record.

What are the most-cited papers on Rebecca Kristeleit?

ScholarIQmost cited works
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher, Kevin Lin, Amit M. Oza, Clare L. Scott, Heidi Giordano, James Sun, Gottfried E. Konecny, Robert L. Coleman, Anna V. Tinker, David M. O’Malley, Rebecca Kristeleit, Ling Ma, Katherine M. Bell‐McGuinn, James D. Brenton, Janiel M. Cragun, Ana Oaknin, Isabelle Ray‐Coquard, Maria I. Harrell, Elaina Mann, Scott H. Kaufmann, Anne Floquet, Alexandra Léary, Thomas C. Harding, Sandra Goble, Lara Maloney, Jeff Isaacson, Andrew R. Allen, Lindsey Rolfe, Roman Yelensky, Mitch Raponi, Iain A. McNeish
The Lancet Oncology. 20161,209 CitationsOPEN ACCESS
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, Víctor Moreno, Rafael López‐López, María Ángeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean‐Pierre Delord, Ahmad Awada, Rebecca Kristeleit, M.E. Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Antón, John Sarantopoulos, Sant P. Chawla, Joaquín Mosquera, M. D’Arcangelo, Armando Santoro, Víctor M. Villalobos, Jacob Sands, Luis Paz‐Ares
The Lancet Oncology. 2020476 Citations
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee, Alexandra Léary, Anna V. Tinker, Kyung Hae Jung, Radosław Mądry, Sang‐Yoon Park, Charles Anderson, Fabian Zohren, Ross Stewart, Caimiao Wei, Samuel S. Dychter, Bradley J. Monk
The Lancet Oncology. 2021415 CitationsOPEN ACCESS
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O’Malley, Ana Oaknin, Michelle Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkıran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Głaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung‐Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Frederick R. Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile Catherine Collins, Kathleen N. Moore, Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit
Journal of Clinical Oncology. 2022395 CitationsOPEN ACCESS
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono
Clinical Cancer Research. 2014362 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · 14-day free trial